TURNSTONE BIOLOGICS CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.05 USD | +6.27% |
|
+12.13% | +19.84% |
| Apr. 16 | Turnstone Biologics Corp. Announces Board Changes | CI |
| Mar. 21 | Turnstone Biologics Corp. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 58.77 | 70.54 | - | - |
| Enterprise Value (EV) 1 | 58.77 | 70.54 | 70.54 | 70.54 |
| P/E ratio | -0.53 x | -1.11 x | -0.95 x | -0.95 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 3.04 x | - | - | - |
| EV / Revenue | 3.04 x | - | - | - |
| EV / EBITDA | -1.05 x | -0.85 x | -0.65 x | - |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 23,093 | 23,128 | - | - |
| Reference price 2 | 2.545 | 3.050 | 3.050 | 3.050 |
| Announcement Date | 3/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 19.31 | - | - | - |
| EBITDA 1 | - | -56.23 | -82.62 | -108.6 | - |
| EBIT 1 | - | -59.03 | -78.4 | -107.4 | -127.8 |
| Operating Margin | - | -305.77% | - | - | - |
| Earnings before Tax (EBT) 1 | - | -55.49 | -67.61 | -99.67 | -127.8 |
| Net income 1 | -30.83 | -55.2 | -74.11 | -103.9 | -121 |
| Net margin | - | -285.92% | - | - | - |
| EPS 2 | -1.560 | -4.780 | -2.760 | -3.220 | -3.225 |
| Free Cash Flow | - | - | - | - | - |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - |
| Announcement Date | 5/15/23 | 3/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | - | - | -17.86 | -18.63 | -20.09 | -18.13 | -21.56 | -25.5 |
| Operating Margin | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | - | -16.62 | -16.84 | -16.97 | -17.12 | -16.69 | -24.59 |
| Net income 1 | -21.52 | -17.32 | -16.45 | -17.93 | -19.54 | -17.01 | -19.63 | -24.59 |
| Net margin | - | - | - | - | - | - | - | - |
| EPS 2 | -7.560 | -1.000 | - | -0.7300 | -0.7300 | -0.5800 | -0.4600 | -0.6800 |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 9/1/23 | 11/13/23 | 3/22/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | -83.5% | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 5/15/23 | 3/22/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
3.05
USD
Average target price
13
USD
Spread / Average Target
+326.23%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +19.84% | 70.54M | |
| -2.61% | 89.08B | |
| +3.55% | 40.9B | |
| -14.40% | 32.25B | |
| +55.89% | 25.14B | |
| -15.96% | 15.39B | |
| -15.50% | 11.91B | |
| -41.29% | 11.89B | |
| -11.75% | 11.64B | |
| +7.87% | 9.03B |
- Stock Market
- Equities
- TSBX Stock
- Financials Turnstone Biologics Corp.
